Tiger Brokers

堃博医疗-B（02216）2026年中期营收3,288千美元，经调整净亏损7,982千美元

公告速递
Sep 18

本季度信息

堃博医疗-B（02216）公布2026年中期财务数据显示，营收为3,288千美元，同比增幅达99%。经调整净亏损为7,982千美元，相比去年同期的6,956千美元同比扩大14.7%。同期毛利2,231千美元，同比提升83.8%，毛利率由上一年同期的67.9%上升至73.5%。经营活动所用现金流量净额为3,883千美元，较去年同期的4,742千美元有所收窄。

在成本方面，报告期内销售及分销开支为3,736千美元，同比上升13%。行政开支同比增加0.75百万美元，达到4,343千美元。研发投入为4,030千美元，在营收快速增长的基础上同比下降9.6%，主要因聚焦核心产品并实施成本优化措施所致。

业务分项

报告期内，中国内地实现收入1,818千美元，同比大幅增长247%；欧盟地区收入1,101千美元，同比增长约14%；其他国家及地区收入369千美元，同比增长129%。公司称，智衡®BroncAblate肺部射频消融系统在中国已累积超过300例临床应用，并覆盖国内30个省市。与此同时，InterVapor®热蒸汽治疗系统也已在全国多地阳光采购平台完成挂网，进一步推动终端应用规模的扩大。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10